Contact
Please use this form to send email to PR contact of this press release:
EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024
TO:
Please use this form to send email to PR contact of this press release:
EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024
TO: